A randomized controlled clinical study of pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia

Shiyong Zhou, Huaqing Wang, Huilai Zhang, Lihua Qiu, Zhengzi Qian, Wei Li, Yun Hou, Kai Fu, Xianming Liu, Xiuzhen Cui

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To compare the efficacy and safety of a single subcutaneous injection of PEG-rhG-CSF and daily rhG-CSF in chemotherapy-induced neutropenia. Methods: In the present randomized, open-label, match, and cross-over study, 78 patients with previously untreated non-small cell lung cancer, breast cancer, and non-Hodgkin's lymphoma with normal bone marrow function were enrolled. The patients were randomized into AB and BA groups. Each patient received two cycles of chemotherapy with identical regimens. In the study cycle, they received a single subcutaneous injection of 100 μg/kg PEG-rhG-CSF on day 3; and in the control cycle, daily subcutaneous infections of 5 μg/kg/d rhG-CSF began on day 3 and continued cither for 14 days or until the absolute neutrophil count (ANC) > 5.0 x 109/L twice post nadir, whichever occurred first. The efficacy and safety parameters were monitored. Results: The incidence of ANC < 1.5 x 109/L in 76 evaluable study cycles and 74 evaluable control cycles were 30.00% and 21.00%, with durations of 2.34 days and 2.31 days, respectively. Additionally, those with grade 4 neutropenia were 3.80% and 3.00%, respectively, in the trial and control cycles. The differences above were not statistically significant. None of the patients experienced febrile neutropenia after receiving PEG-rhG-CSF and rhG-CSF. Compared with that of rhG-CSF, the ANC profile of PEG-rhG-CSF exhibited limited "overshoot" of neutrophils after the nadir. Subgroup analysis according to disease type yielded similar results. The safety profiles of PEG-rhG-CSF and rhG-CSF were similar. Musculoskeletal pain or arthralgias occurred in 16.5% of the cases during the study cycles and 26.00% in the control cycles (P= 0.963), which were mostly mild or moderate. Other adverse effects, such as fever, fatigue, dizziness, gastrointestinal effects and injection-site pain, were transient and easily manageable. Conclusion: A single subcutaneous injection of 100 μg/kg PEG-rhG-CSF provides neutrophil support and a safety profile comparable to daily subcutaneous injections of 5 μg/kg/d rhG-CSF in Chinese patients receiving a variety of myelosuppressive chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)1154-1158
Number of pages5
JournalChinese Journal of Clinical Oncology
Volume38
Issue number18
DOIs
StatePublished - Sep 30 2011

Fingerprint

Neutropenia
Subcutaneous Injections
Neutrophils
Drug Therapy
Safety
Breast Neoplasms
Musculoskeletal Pain
Febrile Neutropenia
Arthralgia
Dizziness
Non-Small Cell Lung Carcinoma
Non-Hodgkin's Lymphoma
Cross-Over Studies
Fatigue
Clinical Studies
human pegylated granulocyte colony-stimulating factor
pegylated granulocyte colony-stimulating factor
Fever
Bone Marrow
Pain

Keywords

  • Clinical trials
  • Drug therapy
  • Granulocyte colony-stimulating factor
  • Neutropenia
  • Polyethylene glycols

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomized controlled clinical study of pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia. / Zhou, Shiyong; Wang, Huaqing; Zhang, Huilai; Qiu, Lihua; Qian, Zhengzi; Li, Wei; Hou, Yun; Fu, Kai; Liu, Xianming; Cui, Xiuzhen.

In: Chinese Journal of Clinical Oncology, Vol. 38, No. 18, 30.09.2011, p. 1154-1158.

Research output: Contribution to journalArticle

Zhou, Shiyong ; Wang, Huaqing ; Zhang, Huilai ; Qiu, Lihua ; Qian, Zhengzi ; Li, Wei ; Hou, Yun ; Fu, Kai ; Liu, Xianming ; Cui, Xiuzhen. / A randomized controlled clinical study of pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia. In: Chinese Journal of Clinical Oncology. 2011 ; Vol. 38, No. 18. pp. 1154-1158.
@article{8ce6d6952ca34043a9970630707673ae,
title = "A randomized controlled clinical study of pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia",
abstract = "Objective: To compare the efficacy and safety of a single subcutaneous injection of PEG-rhG-CSF and daily rhG-CSF in chemotherapy-induced neutropenia. Methods: In the present randomized, open-label, match, and cross-over study, 78 patients with previously untreated non-small cell lung cancer, breast cancer, and non-Hodgkin's lymphoma with normal bone marrow function were enrolled. The patients were randomized into AB and BA groups. Each patient received two cycles of chemotherapy with identical regimens. In the study cycle, they received a single subcutaneous injection of 100 μg/kg PEG-rhG-CSF on day 3; and in the control cycle, daily subcutaneous infections of 5 μg/kg/d rhG-CSF began on day 3 and continued cither for 14 days or until the absolute neutrophil count (ANC) > 5.0 x 109/L twice post nadir, whichever occurred first. The efficacy and safety parameters were monitored. Results: The incidence of ANC < 1.5 x 109/L in 76 evaluable study cycles and 74 evaluable control cycles were 30.00{\%} and 21.00{\%}, with durations of 2.34 days and 2.31 days, respectively. Additionally, those with grade 4 neutropenia were 3.80{\%} and 3.00{\%}, respectively, in the trial and control cycles. The differences above were not statistically significant. None of the patients experienced febrile neutropenia after receiving PEG-rhG-CSF and rhG-CSF. Compared with that of rhG-CSF, the ANC profile of PEG-rhG-CSF exhibited limited {"}overshoot{"} of neutrophils after the nadir. Subgroup analysis according to disease type yielded similar results. The safety profiles of PEG-rhG-CSF and rhG-CSF were similar. Musculoskeletal pain or arthralgias occurred in 16.5{\%} of the cases during the study cycles and 26.00{\%} in the control cycles (P= 0.963), which were mostly mild or moderate. Other adverse effects, such as fever, fatigue, dizziness, gastrointestinal effects and injection-site pain, were transient and easily manageable. Conclusion: A single subcutaneous injection of 100 μg/kg PEG-rhG-CSF provides neutrophil support and a safety profile comparable to daily subcutaneous injections of 5 μg/kg/d rhG-CSF in Chinese patients receiving a variety of myelosuppressive chemotherapy regimens.",
keywords = "Clinical trials, Drug therapy, Granulocyte colony-stimulating factor, Neutropenia, Polyethylene glycols",
author = "Shiyong Zhou and Huaqing Wang and Huilai Zhang and Lihua Qiu and Zhengzi Qian and Wei Li and Yun Hou and Kai Fu and Xianming Liu and Xiuzhen Cui",
year = "2011",
month = "9",
day = "30",
doi = "10.3969/j.issn.1000-8179.2011.18.025",
language = "English (US)",
volume = "38",
pages = "1154--1158",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "18",

}

TY - JOUR

T1 - A randomized controlled clinical study of pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia

AU - Zhou, Shiyong

AU - Wang, Huaqing

AU - Zhang, Huilai

AU - Qiu, Lihua

AU - Qian, Zhengzi

AU - Li, Wei

AU - Hou, Yun

AU - Fu, Kai

AU - Liu, Xianming

AU - Cui, Xiuzhen

PY - 2011/9/30

Y1 - 2011/9/30

N2 - Objective: To compare the efficacy and safety of a single subcutaneous injection of PEG-rhG-CSF and daily rhG-CSF in chemotherapy-induced neutropenia. Methods: In the present randomized, open-label, match, and cross-over study, 78 patients with previously untreated non-small cell lung cancer, breast cancer, and non-Hodgkin's lymphoma with normal bone marrow function were enrolled. The patients were randomized into AB and BA groups. Each patient received two cycles of chemotherapy with identical regimens. In the study cycle, they received a single subcutaneous injection of 100 μg/kg PEG-rhG-CSF on day 3; and in the control cycle, daily subcutaneous infections of 5 μg/kg/d rhG-CSF began on day 3 and continued cither for 14 days or until the absolute neutrophil count (ANC) > 5.0 x 109/L twice post nadir, whichever occurred first. The efficacy and safety parameters were monitored. Results: The incidence of ANC < 1.5 x 109/L in 76 evaluable study cycles and 74 evaluable control cycles were 30.00% and 21.00%, with durations of 2.34 days and 2.31 days, respectively. Additionally, those with grade 4 neutropenia were 3.80% and 3.00%, respectively, in the trial and control cycles. The differences above were not statistically significant. None of the patients experienced febrile neutropenia after receiving PEG-rhG-CSF and rhG-CSF. Compared with that of rhG-CSF, the ANC profile of PEG-rhG-CSF exhibited limited "overshoot" of neutrophils after the nadir. Subgroup analysis according to disease type yielded similar results. The safety profiles of PEG-rhG-CSF and rhG-CSF were similar. Musculoskeletal pain or arthralgias occurred in 16.5% of the cases during the study cycles and 26.00% in the control cycles (P= 0.963), which were mostly mild or moderate. Other adverse effects, such as fever, fatigue, dizziness, gastrointestinal effects and injection-site pain, were transient and easily manageable. Conclusion: A single subcutaneous injection of 100 μg/kg PEG-rhG-CSF provides neutrophil support and a safety profile comparable to daily subcutaneous injections of 5 μg/kg/d rhG-CSF in Chinese patients receiving a variety of myelosuppressive chemotherapy regimens.

AB - Objective: To compare the efficacy and safety of a single subcutaneous injection of PEG-rhG-CSF and daily rhG-CSF in chemotherapy-induced neutropenia. Methods: In the present randomized, open-label, match, and cross-over study, 78 patients with previously untreated non-small cell lung cancer, breast cancer, and non-Hodgkin's lymphoma with normal bone marrow function were enrolled. The patients were randomized into AB and BA groups. Each patient received two cycles of chemotherapy with identical regimens. In the study cycle, they received a single subcutaneous injection of 100 μg/kg PEG-rhG-CSF on day 3; and in the control cycle, daily subcutaneous infections of 5 μg/kg/d rhG-CSF began on day 3 and continued cither for 14 days or until the absolute neutrophil count (ANC) > 5.0 x 109/L twice post nadir, whichever occurred first. The efficacy and safety parameters were monitored. Results: The incidence of ANC < 1.5 x 109/L in 76 evaluable study cycles and 74 evaluable control cycles were 30.00% and 21.00%, with durations of 2.34 days and 2.31 days, respectively. Additionally, those with grade 4 neutropenia were 3.80% and 3.00%, respectively, in the trial and control cycles. The differences above were not statistically significant. None of the patients experienced febrile neutropenia after receiving PEG-rhG-CSF and rhG-CSF. Compared with that of rhG-CSF, the ANC profile of PEG-rhG-CSF exhibited limited "overshoot" of neutrophils after the nadir. Subgroup analysis according to disease type yielded similar results. The safety profiles of PEG-rhG-CSF and rhG-CSF were similar. Musculoskeletal pain or arthralgias occurred in 16.5% of the cases during the study cycles and 26.00% in the control cycles (P= 0.963), which were mostly mild or moderate. Other adverse effects, such as fever, fatigue, dizziness, gastrointestinal effects and injection-site pain, were transient and easily manageable. Conclusion: A single subcutaneous injection of 100 μg/kg PEG-rhG-CSF provides neutrophil support and a safety profile comparable to daily subcutaneous injections of 5 μg/kg/d rhG-CSF in Chinese patients receiving a variety of myelosuppressive chemotherapy regimens.

KW - Clinical trials

KW - Drug therapy

KW - Granulocyte colony-stimulating factor

KW - Neutropenia

KW - Polyethylene glycols

UR - http://www.scopus.com/inward/record.url?scp=80855124839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855124839&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2011.18.025

DO - 10.3969/j.issn.1000-8179.2011.18.025

M3 - Article

AN - SCOPUS:80855124839

VL - 38

SP - 1154

EP - 1158

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 18

ER -